CTOs on the Move

Vitality Biopharma

www.vitality.bio

 
Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vitality.bio
  • 1901 Avenue of the Stars 2nd Floor
    Los Angeles, CA USA 90067
  • Phone: 530.231.7800

Executives

Name Title Contact Details

Similar Companies

New Freedom

New Freedoms 90-day reentry program inspires personal growth and accountability while treating substance abuse and other behavioral health needs.

Fuse Medical

Fuse Medical, Inc., formerly Golf Rounds.com, Inc., is engaged in marketing, distributing and selling internal fixation, bone materials, biologics, tissues, surgical and other related surgical products. The Company operates through medical products and...

Cobb Psychotherapy LCSW

Cobb Psychotherapy is a group private practice providing mental health counseling services. Our therapists practice a range of interventions including evidence-based therapies traditional talk therapy.

Sumitomo Pharma Co.,

Sumitomo Pharma is a pharmaceutical company that develops innovative pharmaceuticals and healthcare solutions for the betterment of healthcare and fuller lives of people worldwide.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.